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Abstract The cytokine tumor necrosis factor alpha (TNF-K) is
a critical e¡ector of the pathogenesis of rheumatoid arthritis
(RA). We used oligonucleotide microarray (OM) analysis to
assess TNF-K-modulated gene expression in cultured primary
human synoviocytes in vitro. Genes identi¢ed include cytokines
and in£ammatory mediators, extracellular matrix and adhesion
molecules, cell cycle and proliferation related proteins, tran-
scription related proteins, and apoptotic mediators. OM identi-
¢ed 1185 di¡erentially expressed genes in TNF-K-treated syno-
viocytes. The regulation of Nef-associated factor-1 (Naf1), an
A20-binding, nuclear factor kappa B (NFUB) inhibitory protein
was probed further given its putative role as an endogenous
brake for the expression of some TNF-K-driven genes. Naf1
mRNA levels were higher in synovial biopsies from patients
with active RA and seronegative arthropathy than in those
from patients with osteoarthritis. These ¢ndings underscore
the value of transcriptome analysis in cytokine-activated syno-
viocyte cultures in vitro as a means of identifying disease-asso-
ciated genes in human arthritis, and implicate Naf1 as a poten-
tial modulator of TNF-K bioactivity in RA.
/ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic in£ammatory auto-
immune disease manifesting complex pathological aspects in
synovial tissues, including hyperplasia of the synovial mem-
brane, in¢ltration by in£ammatory cells, and neovasculariza-
tion. Tumor necrosis factor alpha (TNF-K) is a key in£am-
matory cytokine in the pathogenesis of RA [1,2]. The use of
anti-TNF-K therapy has been very successful in ameliorating
RA in clinical practice. However, this amelioration is only
observed in a subset of the population [3]. Thus, it remains
of interest to de¢ne the downstream mediators and modula-
tors of TNF-K activity in RA.
Fibroblast-like synoviocytes (synoviocytes), are a major
source of the mediators of joint destruction in RA, and are
a dominant cell at the leading edge of invasion by the tumor-
like pannus into adjacent cartilage and bone [4]. Propagation
of synoviocytes in the presence of TNF-K provides a useful in
vitro model with which to dissect out the molecular compo-
nents of TNF-K bioactivity in RA [5,6]. In the present study
we used this model to explore the in£uence of TNF-K on the
synoviocyte transcriptome in vitro, with the goal of identify-
ing RA-associated genes. Speci¢cally, we examined the e¡ects
of TNF-K on the gene expression pro¢le of synoviocytes by
oligonucleotide microarray (OM) analysis and de¢ned disease-
associated expressed gene cohorts. We also identi¢ed Naf1
(Nef-associated factor-1), a putative nuclear factor kappa B
(NFUB) inhibitor, among the TNF-K regulated genes and fur-
ther examined the regulation of its expression.
2. Materials and methods
2.1. Cell culture and cell treatments
2.1.1. Cell culture. Primary human synoviocytes were a kind gift
from Dr. Leslie Cro¡ord, University of Michigan, Ann Arbor, MI,
USA, and were isolated and cultured as previously described [7].
2.1.2. TNF-K stimulation of synoviocytes. Cells were serum starved
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 100 U/
ml penicillin and 100 Wg/ml streptomycin, henceforth referred to as
serum free medium (SFM), for 24 h prior to the addition of 10 ng/ml
TNF-K (RpD Systems Europe Ltd, Abingdon, UK) for the indicated
time periods. Induction of di¡erential gene expression in synoviocytes
by TNF-K was routinely con¢rmed by analysis of vascular cell adhe-
sion molecule-1 (VCAM-1) and intercellular adhesion molecule-1
(ICAM-1) mRNA levels by real-time polymerase chain reaction
(PCR) as described below. In keeping with previous reports [8,9],
TNF-K induced the expression of both genes (data not shown).
2.2. RNA isolation
Synovial membrane biopsies were obtained with Institutional Ethics
Committee approval following informed consent from patients attend-
ing the early arthritis clinic at St Vincent’s University Hospital, Dub-
lin, Ireland. All synovial biopsy specimens were obtained from the
knee at arthroscopy. Patients had been receiving non-steroidal anti-
in£ammatory drugs, but not disease modifying anti-rheumatic drugs.
Patients were diagnosed as having RA, osteoarthritis (OA), or sero-
negative arthritis (SN) according to the criteria of the American Col-
lege of Rheumatology [10]. RNA was isolated from tissues using the
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RNeasy system (Qiagen, UK). Total RNA was isolated from cultured
cells using Trizol (Invitrogen). All procedures were carried out accord-
ing to the respective manufacturer’s instruction.
2.3. Northern blot analysis, reverse transcription (RT)-PCR and
real-time PCR
Northern blotting was performed as described previously [11]. Prior
to performing real-time PCR, residual chromosomal DNA was elim-
inated from total RNA using DNase I (Invitrogen). 2 Wg of total
RNA were reverse transcribed using standard procedures. Quantita-
tive real-time PCR was carried out on cDNA using the ABI Prism
7700 sequence detection system and Taqman1 probe sets (Perkin
Elmer, UK). Cycling conditions were as follows: step 1: 2 min at
50‡C, step 2: 10 min at 95‡C, step 3: 15 s at 95‡C, step 4: 1 min at
60‡C. Steps 3 and 4 were repeated for 40 cycles. Real-time PCR (Taq-
man1) probes were labeled with the £uorescent dyes 5P FAM and 3P
TAMRA as quencher, with the exception of the ribosomal RNA
probe which was labeled with the £uorescent dye 5P VIC in order to
facilitate multiplex analysis. All results were normalized to ribosomal
RNA levels of the sample. Relative expression levels were calculated
with respect to the level in a suitable control sample (see ¢gures) and
are expressed as fold increase or decrease.
2.4. Oligonucleotide microarray analysis
Oligonucleotide microarray analysis was performed using the
A¡ymetrix0 Gene Chip Expression Analysis system (High Wycombe,
UK). Oligonucleotide microarray experiments were carried out using
RNA samples isolated from cultured synoviocytes which had been
stimulated with TNF-K for 0, 4 or 24 h. The entire experiment and
analysis was carried out independently in triplicate. RNA samples
were further puri¢ed using the RNeasy system from Qiagen. Sample
preparation and subsequent analysis were carried out according to the
manufacturer’s instructions. The hybridization quality and array per-
formance were assessed using the GeneChip0 eukaryotic hybridiza-
tion control kit and Test 2 arrays (A¡ymetrix0). Changes in gene
expression were accessed by comparing the expression pro¢le at 0 h
with those at 4 and 24 h obtained by hybridization of the respective
cRNAs to Hu95A Gene Arrays (A¡ymetrix0) which are representa-
tive of V12 650 unique human expressed genes.
2.5. Microarray data analysis
The information generated from the replicate experiments was an-
alyzed using GeneSpring1 Version 5.1 from Silicon Genetics. The
microarray data were normalized to the distribution of all probe
sets to control for systematic variation, and also to the median of
each probe set to account for any di¡erences in detection e⁄ciency.
This normalization facilitated the identi¢cation of changes in gene
expression levels, which were indicative of biological variation and
not variations due to measurement processes. As large numbers of
replicate experiments could not be performed, the global error model
was used to estimate measurement and sample-to-sample variation.
3. Results and discussion
3.1. Analysis of di¡erential gene expression in
TNF-K-stimulated synoviocytes by oligonucleotide
microarray analysis
Oligonucleotide microarray analysis was performed using
Fig. 1. A: Induced gene expression at 4 and 24 h post-TNF-K stimulation. Graphs of the log values of normalized expression ratios for genes
induced v 2-fold by TNF-K at both 4 and 24 h (231), v 2-fold exclusively at 4 h (148), and v 2-fold exclusively at 24 h (184). Pie charts rep-
resent the subsets of functionally assigned genes from the lists represented in the graphs. The number of genes functionally assigned relative
to the total number in each group is de¢ned as follows: 121/231, 59/148 and 62/184. Color coding for signal intensity and for functional
assignment is indicated. B: TNF-K suppressed transcription at 4 and 24 h post-TNF-K stimulation. Graphs of the log values of normalized ex-
pression ratios for genes with v 2-fold reduced transcription with TNF-K at both 4 and 24 h (128), v 2-fold reduced exclusively at 4 h (138),
and v 2-fold reduction exclusively at 24 h (356). Pie charts represent the subsets of functionally assigned genes from the lists depicted in the
graphs. The number of genes functionally assigned relative to the total number in each group is de¢ned as follows: 37/128, 33/134 and 75/331.
Color coding for signal intensity and for functional assignment is indicated.
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the A¡ymetrix Hu95A array representing over 12 000 genes
and RNA from synovial ¢broblast which were unstimulated
or stimulated with TNF-K for 4 or 24 h. To validate the
di¡erential expression of genes identi¢ed by OM, Northern
blotting and real-time PCR were used. These techniques qual-
itatively con¢rmed modulation of gene expression by TNF-K
of a representative cohort of genes. In all the expression of six
genes was veri¢ed. The data on Naf1, presented below, serve
as an example. Our OM analysis indicated that the expression
of 231 genes was signi¢cantly induced in response to TNF-K
at both 4 and 24 h, that the expression of 148 was signi¢cantly
induced in response to TNF-K at 4 h only, and that the ex-
pression of 184 genes was induced only at 24 h. OM analysis
also illustrated that the expression of 128 genes was signi¢-
cantly suppressed in response to TNF-K at both 4 and 24 h,
that the expression of 138 genes was signi¢cantly suppressed
in response to TNF-K at 4 h only, and that the expression of
356 genes was suppressed only at 24 h. These changes are
represented graphically in Fig. 1A and B. A complete list of
genes and their expression levels will be lodged at http://
www.ncbi.nlm.nih.gov/geo/ :GSE516. In order to dissect how
changes in gene expression pro¢les in synoviocytes in response
to TNF-K treatment may relate to disease progression in RA,
¢ve disease-associated expressed gene groups were de¢ned
within the data sets. These were cytokines and in£ammatory
mediators, extracellular matrix proteins and adhesion mole-
cules, cell cycle and proliferation related proteins, transcrip-
tion related proteins, and ¢nally apoptotic mediators. The
induction and suppression of the disease-associated functional
groups over time are represented by the pie charts in Fig. 1A
and B.
From Fig. 1A it is clear that there is a dramatic and main-
tained induction of cytokine and in£ammatory gene expres-
sion with the addition of TNF-K to synoviocytes. The induc-
tion of expressed genes such as interleukin (IL)-8, IL-6,
RANTES and MCP-1 is consistent with the current knowl-
edge about the contribution of synoviocytes to RA. The
consistent induction of substantial numbers of extracellular
matrix proteins and adhesion molecules such as matrix
metalloproteinases (MMPs) and VCAM is also consistent
with current hypotheses on disease progression in RA. The
suppression of a signi¢cant number of transcription related
genes was observed, and will be the subject of further study.
3.2. Disease-associated genes with potential pathophysiological
roles in RA
One distinct cohort of genes identi¢ed as di¡erentially regu-
lated in response to TNF-K were the interferon (IFN) respon-
Table 1
TNF-K induced IFN responsive and NFUB signalling gene transcripts
Genes were chosen and clustered on the basis of their belonging to a particular group of related genes. The levels of mRNA expression at each
of the three time points (0, 4 and 24 h) are represented by three colored boxes in the color panel, the relative expression level is represented on
the scale above.
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sive genes. IFN-Q has the ability to alter the balance of extra-
cellular matrix synthesis and degradation, and decreases levels
of type I and type III pro-collagen mRNA in RA synovio-
cytes [12]. IFN-Q can also inhibit collagen synthesis and metal-
loproteinase production in synoviocytes that have been stimu-
lated by TNF-K. TNF-K and IFN-Q may thus have inverse
e¡ects on many aspects of synoviocyte function, a phenome-
non that has been termed mutual antagonism [12]. 16 IFN
regulated and modulated genes were identi¢ed. One such
IFN-induced gene, IP-30 (GILT), has been previously identi-
¢ed as upregulated by an SSH analysis which compared genes
expressed in OA tissues with those expressed in RA tissues
[13]. Also induced were target genes of the IFN-Q pathway
such as TRAIL and pim-1 [14,15].
Also among the IFN-induced genes identi¢ed were the
IFN-stimulated transcription factors, IFN regulatory factor-
1 (IRF-1), and IFN-stimulated transcription factor-3 (ISGF3)
component. IRF-1 can activate the transcription of both the
IFN-K and IFN-L genes [16]. The IFN-dependent transcrip-
tion factor ISGF3 acts as a multiprotein complex [17]. In its
latent state ISGF3 exists as two independent components,
ISGF-K and ISGF3-Q. ISGF-K comprises three polypeptides,
including signal transducers and activators of transcription
(STAT)1 and 2. STAT4 and STAT5a were also detected as
induced in response to TNF-K (Table 1). Elevated levels of
STAT4 expression have been previously demonstrated in ac-
tivated macrophages present at the site of in£ammation in RA
[18], whereas STAT5a has been suggested to be involved in
T-cell proliferation [19]. The advent of anti-IFN therapy for
the treatment of rheumatoid disease has had mixed results
[20^22]; thus, identifying TNF-K regulated cohort of IFN
responsive genes, including downstream regulators of IFN
action, may help in de¢ning the e¡ects of such therapies on
downstream signalling events in RA.
3.3. Induction of Naf1 gene expression by TNF-K in
synoviocytes
Our OM analysis revealed for the ¢rst time the expression
of Naf1 in human synoviocytes and its association with TNF-
K stimulation in this model system. Naf1 is the human homo-
log of murine A20-binding inhibitor of NFUB (ABIN-1),
which binds A20 and can inhibit NFUB-dependent gene ex-
pression [23]. ABIN-1 was originally detected in a yeast two-
hybrid screen [24] and has been shown to interact with the
C-terminal part of A20 and to colocalize with A20 in the cell
cytoplasm. Overexpression of ABIN-1 blocks NFUB activa-
tion by TNF-K, and it is thought that this may occur at the
level of TRAF2 [25]. It had been postulated that through its
interaction with A20, ABIN-1 may modulate the inhibitory
e¡ect of A20 on NFUB signalling [24]. However, recent evi-
dence suggests that the interaction of ABIN-1 with A20 may
not be required for NFUB inhibition by either protein, in vitro
[26]. Thus, the exact mechanism of NFUB inhibition by A20
and its interacting proteins in vivo is still unclear. The kinetics
of Naf1 induction was examined by quantitative PCR after
stimulation with TNF-K. The expression of Naf1 in response
to TNF-K was maximal at 8 h over the course of 24 h as
illustrated in Fig. 2. Previous array studies examining synovi-
ocyte gene expression in response to TNF-K did not detect
Naf1 [27]. However, this is probably due to the fact that 24 h
was the only time point examined, and the kinetics of Naf1
induction indicate that expression of Naf1 is maximal at 8 h.
A recent study has shown induction of Naf1 in TNF-K-stimu-
lated HeLa cells and inhibition of its expression following
disruption of the p65 NFUB subunit, indicating that the ex-
pression of Naf1 is NFUB dependent [28]. These ¢ndings are
consistent with those of others [29,30]. In this study we also
found induction of the expression of A20 in response to TNF-
K in synoviocytes (Table 1). Therefore, it may be suggested
that parallel induction of Naf1 and A20 in in£amed synovio-
cytes o¡ers potential targets through which the NFUB path-
way could be regulated therapeutically.
3.4. Analysis of Naf1 mRNA levels in tissue biopsies from
arthritis patients
Naf1 mRNA levels were also analyzed in tissue biopsies
from two types of in£ammatory arthritis, RA and SN (neg-
ative for rheumatoid factor) and compared to expression lev-
els in tissue samples from patients su¡ering from the non-
in£ammatory arthritis, OA. Two independent analyzes were
carried out using quantitative real-time PCR and the results
are presented as series 1 and 2 in Fig. 3. Relatively high levels
of Naf1 expression were observed in patients su¡ering from
in£ammatory arthritis compared to those with non-in£amma-
Fig. 3. Analysis of Naf1 mRNA expression levels in tissue samples
from patients with arthritis by quantitative real-time PCR. Each se-
ries represents an independent group of patient samples. Fold
change is relative to the OA samples.
Fig. 2. Kinetics of induction of Naf1 mRNA in synoviocytes in re-
sponse to TNF-K. TNF-K (10 ng/ml) was added for 15 min^24 h to
synoviocyte cultures that had been serum starved overnight. Naf1
mRNA expression levels were determined by quantitative real-time
PCR. These results are an average of ¢ve separate duplicate experi-
ments. Error bars represent S.E.M.
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tory arthritis (Fig. 3). These results link high levels of expres-
sion of Naf1 with in£ammatory disease states. As elevated
levels of NFUB are associated with in£ammatory arthritis, it
may appear contradictory that elevated levels of Naf1 expres-
sion (an NFUB inhibitor) are also detected. However, it may
be suggested that these elevated levels of Naf1 play a role in
negative feedback regulation of NFUB expression, and there-
fore suggest a possible contribution of this gene product to
modulating the TNF-K/NFUB in£ammatory drive in RA in
humans.
Our studies have shown Naf1 to be a TNF-K inducible,
disease-associated gene. A recent study has shown that Naf1
can also bind the MAP kinase ERK2 and cause its retention
in the cytoplasm, which in turn leads to a reduction of ERK2
nuclear signalling [31]. Thus, Naf1 may attenuate both NFUB
and ERK signalling in human synoviocytes. The e¡ects of
Naf1 on the regulation of ERK signalling and the expression
of other A20 interacting NFUB regulators such as ABIN-2 in
the context of rheumatoid disease will be further investigated.
In conclusion, this study has identi¢ed cohorts of cytokines
and in£ammatory mediators, extracellular matrix and adhe-
sion molecules, cell cycle related proteins, transcription related
proteins, and apoptotic mediators, whose expression is asso-
ciated with an experimental model of RA progression. Of
particular interest is the association of elevated Naf1 expres-
sion with RA. It suggests that natural inhibitors of the TNF-
K^NFUB signalling pathway might have value as a future
therapeutic target.
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